At Syndax, we are advancing the next generation of targeted treatments to realize a future in which people with cancer live longer and better than ever before.
We are a clinical stage oncology innovator developing first-in-class therapies for acute leukemias and chronic graft-versus-host disease. Our team is committed to adhering to scientific excellence and dedicated to serving the patient community by delivering therapeutics that provide meaningful and differentiated clinical results and address urgent unmet need.
With a steadfast commitment to our mission of obtaining regulatory approval and commercializing drugs that extend and improve the lives of cancer patients, we are oncology leaders advancing differentiated and targeted cancer therapies. Highlights of our innovative pipeline include two candidates, revumenib and axatilimab, in late-stage development with the potential to be approved in the U.S. in 2024.
Revumenib is a potent, selective, small molecule inhibitor of the menin-KMT2A interaction being developed for the treatment of KMT2A-rearranged acute leukemias, including acute lymphoblastic leukemia and acute myeloid leukemia (AML), and NPM1-mutated AML.Explore More
Axatilimab is an investigational monoclonal antibody that targets colony stimulating factor-1 receptor, or CSF-1R, a cell surface protein thought to control the survival and function of monocytes and macrophages, being developed for chronic graft-versus-host disease and idiopathic pulmonary fibrosis.Explore more